Cys-mAb Conjugation Sequence for Site-Specific Antibody Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing site-specific antibody conjugates using cysteine mutant antibodies (Cys-mAbs) are hindered by the chemical similarity between engineered cysteine thiol groups and native disulfides, leading to inefficient conjugation and inconsistent product quality due to undesired reactions.
Innovation Solution
A method involving cysteine blocking, selective reduction, oxidation, and conjugation steps, including cation exchange chromatography and buffer exchange, to prepare homogeneous antibody conjugates, using agents like TPPTS, TCEP, and DHAA, to ensure high yield and consistency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a reducing agent is added to remove caps from engineered cysteine, then the cysteine thiol groups become available for conjugation, but native disulfides are also reduced causing undesired conjugation at wrong locations
Solution Approach 1:
The patent segments the reduction process into two distinct stages: first selective reduction of engineered cysteine caps using a first reducing agent, then oxidation and subsequent conjugation, and finally reduction of any remaining disulfides using a second reducing agent. This segmentation allows each reduction step to occur under optimized conditions that prevent unwanted side reactions.
Solution Approach 2:
The patent applies preliminary oxidation after the first reduction step to convert reduced native disulfides back to disulfide bonds before conjugation. This preliminary action prevents unwanted conjugation at native disulfide sites by restoring their oxidized state before the conjugation reaction occurs.
2Ease of manufacture
If non-specific chemistry is used to manufacture antibody-drug conjugates, then manufacturing complexity is reduced, but product quality consistency deteriorates
Solution Approach 1:
The patent introduces local quality by creating distinct chemical environments at different stages of the process. The engineered cysteine cap has unique properties that allow selective reduction under specific conditions (pH, reducing agent type), while native disulfides require different conditions. This local differentiation enables selective modification at desired sites while preserving other functional groups.
Solution Approach 2:
The patent systematically changes multiple parameters throughout the process: pH levels (maintaining pH 5.0-7.0 during reduction), reducing agent selection (TPPTS, TCEP, or borane), oxidation agents (iodine, hydrogen peroxide), and timing sequences. These parameter changes create controlled conditions that achieve site-specific conjugation with high consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the production of site-specific antibody conjugates with high yield and consistent product quality by selectively uncapping engineered cysteines, allowing for controlled conjugation reactions.
Implementation Method 1
exposing the antibody or antibody fragment to a cysteine blocking agent, wherein the cysteine blocking agent forms a stable mixed-disulfide with at least one cysteine residue of the antibody or antibody fragment
Implementation Method 2
adding a reducing agent to the composition to form a reduction mix and allowing a reduction reaction to occur such that the reduction mix comprises a reduced antibody or reduced antibody fragment
Implementation Method 3
adding an oxidizing agent to the reduction mix to form an oxidized mix and allowing an oxidizing reaction to occur such that the oxidized mix comprises an oxidized antibody or oxidized antibody fragment
Implementation Method 4
adding an activated chemical moiety to the oxidized mix to form a conjugation mix and allowing a conjugation reaction to occur such that an antibody conjugate or antibody fragment conjugate is formed
Implementation Method 5
following step b) and before step c) cation exchange chromatography is performed to remove excess cysteine blocking agent
Implementation Method 6
In one embodiment, the buffer exchange step is ultrafiltration/diafiltration
Data Source
AI summary
The present disclosure relates to a method of capping, reducing, and oxidizing cys-mAbs in order to provide homogenous material for subsequent conjugation reactions. The present method demonstrates robust ways to manufacture conjugates of cysteine-engineered antibodies that offer high yield and consistent product quality.